期刊文献+

细粒棘球蚴囊经甲苯达唑、阿苯达唑或阿苯达唑亚砜作用后其生发层的形态学变化和药物含量 被引量:1

Morphological Alteration and Drug Content in Cyst Wall of Echinococcus granulosus Exposed to Mebendazole, Albendazole or Albendazole Sulfoxide
暂未订购
导出
摘要 小鼠的继发性细粒棘球蚴囊在含甲苯达唑阿苯达唑或阿苯达唑亚枫1及10μg/ml的培养液中培养l~7d时,囊壁所含各药物的量相近,但生发层的受损以甲苯达唑组较重,次为阿苯达唑亚砜和阿苯达唑组。感染小鼠ig上述3种苯并咪唑类化合物的等效剂量1~14d后24h,囊壁的药物含量甚低,但生发层的损害仍以甲苯达唑组的较重,并认为阿苯达唑亚矾是阿苯达唑的有效代谢物。 When secondary cysts of Echinococcus granulosus, removed out from mice infected with protoscoleces 12-14 months previously, maintained in vitro were exposed to mebendazole (Meb), albendazole (Alb) or albendazole sulfoxide (AlbSO) at a concentration of 1 or 10 μg / ml for 1, 3 and 7 d, the contents of each drug in cyst wall were similar. Meanwhile, the alteration in germinal layer induced by Meb was more apparent as compared with that induced by AlbSO and Alb. When infected mice were treated ig with Meb, Alb or AlbSO at an equal effective dose of respective 50, 300 and 150 mg/ kg daily for 1, 3, 7 and 14 d, more severe damage in germinal layer was seen in Meb group. In comparison with Alb and AlbSO, the damage in germinal layer induced by the latter was more intensive than that induced by the former. 24h after last dose of each treatment course, much less Meb, Alb or AlbSO was detected in cyst wall. The results indicate that the germinal layer of E. granulosus is more susceptible to Meb than to Alb and AlbSO, and convince that AlbSO is the major effective metabolite of Alb.
出处 《地方病通报》 1992年第1期5-10,共6页 Endemic Diseases Bulletin
关键词 细粒棘球蚴囊 甲苯达唑 阿苯达唑 Echinococcus granulosus cyst Germinal layer Mebendazole Albendazole Albendazole sulfoxide
  • 相关文献

参考文献1

二级参考文献2

共引文献13

同被引文献49

  • 1何颖娜,尚京川,张晓萍,母昭德,景淑华,封家富.高效液相色谱法测定人血浆中甲苯咪唑含量[J].第三军医大学学报,2005,27(20):2086-2087. 被引量:8
  • 2杨元清,张超威,肖树华,尤纪青,吴嘉彤,柴君杰,张文林.吡喹酮、甲苯达唑及阿苯达唑对细粒棘球蚴作用的组织化学比较[J].地方病通报,1990,5(3):21-25. 被引量:5
  • 3肖树华,尤纪青,焦佩英,郭惠芳,黄立信,柴君杰,焦伟.甲苯达唑、阿苯达唑及其代谢物实验治疗小鼠继发性细粒棘球蚴病的研究[J].地方病通报,1990,5(3):11-16. 被引量:14
  • 4Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop [J]. Z Parasitenkd, 1982, 67(1): 5-26.
  • 5Munst GJ, Karlaganis G, Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results [J]. Eur J Clin Pharmacol, 1980, 17(5): 375-378.
  • 6Keystone JS, Murdoch JK. Mebendazole[J]. Ann Int Med, 1979, 91(4): 582-586.
  • 7Morris DL, Dykes PW, Dickson B, et al. Albendazole in hydarid disease[J]. Br Med J (Clin Res Ed), 1983, 286(6359): 103-104.
  • 8Dawson M, Braithwaite PA, Roberts MS, et al. The pharmacokinetics and bioavailability of a tracer dose of [^3H]-mebendazole in man[J]. Br J Clin Pharmacol, 1985, 19(1): 79-86.
  • 9Davis A, Pawlowski S, Dixon H. Muhicentre clinical trials of benzimidazole carbamates in human echinococcosis[J]. Bull WHO, 1986, 64(3): 383-388.
  • 10Davis A, Pawlowski S, Dixon H. Multicentre clinical trials of benzimidazole carbalnates in human echinococcosis (phase 2) [J]. Bull WHO, 1989, 67(5): 503-508.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部